2017 Senate Joint Resolution 20
Relating to: designating June 2017 as Myasthenia Gravis Awareness Month.
Whereas, myasthenia gravis (MG) is an autoimmune neuromuscular disease that causes chronic weakness, in which antibodies attack receptors in the body and prevent muscle contraction; and
Whereas, MG frequently weakens muscles that control eye movement, facial expressions, and swallowing, and its symptoms may include blurred vision, speech impairment, difficulty chewing, shortness of breath, an unstable gait, and a weakened grip; and
Whereas, a diagnosis of MG may be missed or delayed because its symptoms are in common with many other disorders; and
Whereas, in some cases MG symptoms can worsen to the point of disability, grave illness, or death, if there are gaps in or an absence of the several crucial health care treatments that can enable those who endure MG to lead productive, active lives of normal longevity; and
Whereas, MG is found most commonly in adult women under 40 and men over 60, but is not specific to either gender or any particular ethnic background; and
Whereas, MG is nonhereditary and noncontagious; and
Whereas, 10 to 20 out of every 100,000 Americans are diagnosed with MG, and for those people support groups exist in Wisconsin; now, therefore, be it
Resolved by the senate, the assembly concurring, That June 2017 is hereby designated Myasthenia Gravis Awareness Month in Wisconsin.